TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Medication-based Analgesia in Humans- STUDY 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-75~* Urine sample tests negative for common illicit substances of abuse, including cannabis~* Medically cleared to take study medications~* Are not pregnant or breast feeding~* Willing to comply with the study protocol.~Exclusion Criteria:~* Meet DSM-5 criteria for alcohol/substance use disorder~* Taking opioids for pain~* Previous adverse reaction to a cannabinoid product~* Prescribed and taking stimulants or benzodiazepines~* Answer yes to item 1 of the Brief Pain Inventory indicating chronic pain~* Self-report any illicit drug or cannabinoid use in the past 7 days~* Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse event~* History of seizure disorder~* Have a known allergy to the study medications or sesame seed oil~* ALT or AST levels \>3x ULN and/or Bilirubin levels \>2x ULN during Screening~* Current (past 60-day) suicidal thoughts or past year history of suicidal behavior~* Taking medications contraindicated with hydromorphone or cannabidiol~* Have a history of clinically significant cardiac arrhythmias or vasopastic disease~* Have an abnormal and clinically-significant ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo+Placebo (Type: PLACEBO_COMPARATOR): Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
- Hydromorphone+Placebo (Type: ACTIVE_COMPARATOR): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
- Hydromorphone (oral) 4mg + Cannabidiol 50mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 50mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg + Cannabidiol 100mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 100mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg + Cannabidiol 200mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 200mg. Order of dose randomized session days 2-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Understanding Alcohol Reward in Social Context

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 21 and 30~* Currently drinks alcohol~* Able to provide at least 2 same-gender friend referrals~Exclusion Criteria:~* Female participant is pregnant or trying to become pregnant~* Endorsed medical disorder caused by, or made worse by, alcohol~* History of severe alcohol problems~* Use of drugs known to interact with alcohol

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Alcohol Administration (Type: EXPERIMENTAL): A moderate dose of alcohol (Target BAC .08%)
- Control Beverage Administration (Type: NO_INTERVENTION): Participants consume a non-alcoholic beverage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Chronic hepatitis C, Genotype 2 or 3~* Naïve to prior anti-HCV therapy~Exclusion Criteria:~* Infected with HCV other than Genotype 2 or 3~* Positive Hepatitis B surface antigen (HBsAg), or Human immunodeficiency virus-1 (HIV-1)/HIV-2 antibody at screening~* Evidence of liver disease other than HCV~* Active substance abuse~* Evidence of decompensated cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir (Type: EXPERIMENTAL): None
- Arm 2: pegIFNλ + Ribavirin + Daclatasvir (Type: EXPERIMENTAL): None
- Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Anti-IgE in Severe Childhood Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children between the ages of 4-19 years~2. Severe eczema~3. Raised SpIgE or SPT to at least 1 food allergen or 1 aeroallergen AND/OR~4. Clinical impression that allergic exposures cause worsening eczema.~5. Total IgE level \>300 kU/l~6. Clinically proven IgE-mediated allergic disease.~7. Written informed consent to participate.~Exclusion criteria:~1. Inability to comply with 2-4 weekly injections and clinic visits~2. Evidence of underlying immune compromise, autoimmune disease, immune complex mediated conditions.~3. Uncontrolled infection or unstable eczema.~4. Malignancy or a history of malignancy.~5. Pre-existing hepatic or renal impairment~6. Known cardiovascular or ischaemic cerebrovascular abnormality.~7. Other serious or uncontrolled systemic disease.~8. Pregnancy or lactation.~9. Known history of hypersensitivity or anaphylaxis to anti-IgE injections or its constituents.~10. Insufficient understanding of the trial assessments.~11. Participation in a CTIMP in the previous 60 days or (if known) 4 half-lives of the relevant medication, whichever is the greater.~12. Investigator feels that there is a good clinical reason why the child would be unsuitable.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Xolair/Omalizumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Facilitation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have mild Alzheimer's Disease or Mild Cognitive Impairment (MCI);~* age between 55-85;~* Mini Mental Status Exam (MMSE) between 15-26;~* a caregiver who can provide information, and bring patient to the sessions;~* no known allergies to any of the medications to be used;~* normal renal function; willingness of patient and spouse/responsible caregiver to participate.~Exclusion Criteria:~* Significant Psychiatric disorder;~* stroke; current use of any of the test medications (e.g., statin, L-Arginine, Kuvan);~* phenylketonuria (PKU) ;~* elevated serum phenylalanine level (\>10 mg/dL);~* allergy to any of the medications; current active malignancy;~* renal insufficiency (elevated creatinine above 1.3mg/dl);~* abnormal liver function (Alanine Aminotransferase (ALT) or Aspartate Transaminase (AST) 2x normal);~* other serious disease including coronary insufficiency or congestive heart failure, carotid stenosis greater than 50%, active peptic ulcer, urinary tract or other active infection, cancer (except skin cancer, or 5 years inactive breast or prostate cancer )etc.;~* pregnancy; or~* inability to come to UMass for follow-up. Subjects may continue to take anticholinesterase drugs for Alzheimer's Disease (Aricept, Exelon, Razadyne) and/or Namenda, if they have been on the drug(s) for at least 3 months. Subjects on levodopa and male subjects taking drugs for erectile dysfunction (Viagra, Cialis, Levitra) are cautioned regarding hypotension.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin + L-Arginine + Tetrahydrobiopterin (Type: EXPERIMENTAL): Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Cysteine in Trichotillomania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women age 18-65;~* current DSM-IV trichotillomania~Exclusion Criteria:~* unstable medical illness;~* history of seizures;~* myocardial infarction within 6 months;~* current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~* any thoughts of suicide;~* lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;~* previous treatment with N-Acetyl Cysteine;~* treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;~* 9) diagnosis of asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Cysteine (Type: ACTIVE_COMPARATOR): N-Acetyl Cysteine
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who require continuous low-dose aspirin therapy during the treatment period with the study drug~2. Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed~3. Outpatient (including inpatient for examinations)~Exclusion Criteria:~1. Participants scheduled to change the type and dosage regimen of low-dose aspirin~2. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed~3. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology~4. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery~5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~6. Participants with a previous or current history of aspirin-induced asthma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 10 mg QD (Type: EXPERIMENTAL): None
- TAK-438 20 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 15 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Techniques of Local Anaesthesia During Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective laparoscopic cholecystectomy~* 18 years old or over~Exclusion Criteria:~* Emergency surgery~* Under 18 year olds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: SHAM_COMPARATOR): Sham wash, sham injection
- Subperitoneal injection (Type: EXPERIMENTAL): Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
- Topical LA (Type: ACTIVE_COMPARATOR): Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (patients, as appropriate)~* Genetically-confirmed Prader-Willi syndrome and hyperphagic~* In a stable care setting for at least 6 months prior to Visit 1~* Caregiver must have been caring for the patient for at least 6 months prior to Visit 1~Exclusion Criteria:~* Have participated in an interventional clinical study (i.e., investigational drug or device, approved drugs or device evaluated for unapproved use) within prior 3 months~* Positive urine pregnancy test (in females of child-bearing potential) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation~* Any other known disease and/or condition, which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCCR (Type: EXPERIMENTAL): 75 - 450 mg DCCR
- Placebo (Type: PLACEBO_COMPARATOR): 75 - 450 mg placebo for DCCR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of SLE~* Active SLE~* On stable background therapy for 1 month~* Using highly effective contraception~Exclusion Criteria:~* Serious organ failure (renal functional impairment, severe central nervous system manifestations, severe heart failure, liver failure)~* Any clinical evidence of active chronic infection HIV, hepatitis B, hepatitis C~* Clinical significant pleuritis or pericarditis~* Type1 Diabetes and/or CROHN's disease~* Use of Benlysta (belimumab) in the past 4 weeks~* Use of Rituximab in the past 6 months~* Vaccination with live attenuated virus in the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ILT-101 (Type: EXPERIMENTAL): Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients implanted with a HeartMate 3 LVAD~2. Age 18 or greater and able to provide written informed consent~3. Females of childbearing age must agree to adequate contraception~Exclusion Criteria:~1. History of post-LVAD device thrombosis, stroke, or gastrointestinal bleeding~2. Patients who are bridge to transplant and a current UNOS status 1-3~3. Ongoing inotrope therapy after LVAD (e.g., milrinone, dobutamine, epinephrine)~4. Permanent right ventricular assist device at the time of LVAD implant~5. Patients with a mechanical heart valve~6. Patients with end-stage renal disease on dialysis~7. Pregnant patients~8. Known history of ischemic stroke, intracranial bleed, or neurosurgery within 3 months~9. Known history of intracerebral arteriovenous malformation, cerebral aneurysm or mass lesions of the central nervous system.~10. Recent (\<48 hours) or planned spinal or epidural anesthesia or puncture~11. Prior history of known thrombophilia (e.g., factor V Leiden, prothrombin gene mutation, protein C or S deficiency, antithrombin 3 deficiency, hyperhomocysteinemia, antiphospholipid antibody syndrome) or indication for higher INR goal (\>2.5) with warfarin.~12. Thrombolysis within the previous 7 days~13. Patients with an allergy or contraindication to aspirin, warfarin, or apixaban~14. Patients on antiplatelet therapy other than aspirin (e.g., clopidogrel, prasugrel, ticagrelor, dipyridamole, or pentoxifylline)~15. Patients on combined P-glycoprotein and strong CPY3A4 inhibitors or inducers (e.g., fluconazole, posaconazole, rifampin)~16. Known bleeding within the last 30 days requiring emergency room presentation or hospitalization~17. Known history of an inherited bleeding disorder (e.g., hemophilia, von Willebrand disease)~18. Patients with active bleeding or a hemoglobin \< 8.0 g/dl~19. Total bilirubin \> 2.0 mg/dl, shock liver, hepatic encephalopathy, or biopsy proven liver cirrhosis~20. INR \> 2.0 not due to anticoagulation therapy~21. Platelet count \<100,000 cells/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
- Warfarin (Type: ACTIVE_COMPARATOR): LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted indications:~2. At least 18 years of age~3. Otherwise in good health, as determined by physical exam and medical history~4. If female, and of child-bearing potential, is using an acceptable form of birth control~5. Negative urine pregnancy test at screening, if applicable~6. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~1. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon~2. Subjects with impaired consciousness that predisposes them to pulmonary aspiration~3. Subjects who are undergoing colonoscopy for foreign body removal and decompression~4. Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics~5. Subjects who are taking drugs that may affect electrolyte levels with the exception of routine diuretics~6. Subjects with known clinically significant electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia~7. Subjects who are pregnant or lactating, or intending to become pregnant during the study~8. Subjects of childbearing potential who refuse a pregnancy test~9. Subjects who are allergic to any preparation components~10. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures~11. Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HalfLytely with 10mg bisacodyl (Type: ACTIVE_COMPARATOR): Active control
- HalfLytely with 5mg bisacodyl (Type: EXPERIMENTAL): Investigational dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good general health~* Have 5 to 20 AKs on the face or balding scalp~* Negative urine pregnancy test (for women who are able to become pregnant)~* Willing to make frequent visits to the study center during treatment and follow-up periods.~Exclusion Criteria:~* Women who are pregnant, lactating or planning to become pregnant during the study.~* Have had a medical event within 90 days of the first visit (such as; stroke, heart attack).~* Have any skin condition in the treatment area that may be made worse by treatment with imiquimod (e.g., rosacea, psoriasis, atopic dermatitis, eczema).~* Have received specific treatments/medications in the treatment area(s) within the designated time period prior to study treatment initiation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3.75% imiquimod cream (Type: ACTIVE_COMPARATOR): None
- 2.5% imiquimod cream (Type: ACTIVE_COMPARATOR): None
- Placebo cream (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete